Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Medexus Pharmaceuticals Inc. (V:MDP)

Business Focus: Pharmaceuticals

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for MDP within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jun 22, 2020 17:15 ET
Medexus Pharmaceuticals Reports Record Revenue of $25.6 Million and $4.2 Million of Adjusted EBITDA* for the Fourth Quarter of Fiscal 2020
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today provided a business update and announced its financial and operating results for the fourth quarter and fiscal year ended March 31, 2020.  All dollar amounts...
Read full article
Jun 17, 2020 09:15 ET
Medexus Pharmaceuticals Schedules Fiscal Year 2020 Conference Call
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Tuesday, June 23, 2020 to discuss the Company’s financial results for the fiscal...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.30
--
--
Price to Sales - TTM
0.72
4.82
8.15
Price to Book - most recent quarter
1.55
2.60
2.56
Price to Cash Flow per share - TTM
23.54
9.01
11.05
Price to Free Cash Flow per share - TTM
--
13.05
22.27
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jun 15, 20201,977-3,300
May 31, 20205,2772,069
May 15, 20203,2082,607
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Medexus Pharmaceuticals Inc, formerly Pediapharm Inc, is a Canada-based company engaged in pharmaceutical business sector. The Company is a North American focused, specialty pharmaceutical business that operates through three segments: Medac Pharma USA, a fully integrated commercial infrastructure focused on auto-immune diseases in the United States; Medexus Pharma Canada, a fully integrated commercial infrastructure focused on auto-immune disease and pediatric diseases in Canada; and a Business Development function, which works to maintain its product pipeline. The Company's flag products are Rasuvo and Metoject, a formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an allergy medication. The Company provides products for the healthcare professionals and patients.

See business summary

 

Twitter

Search (past week) for $MDP.CA MDP.V

  • No tweets found